Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3510LO1W
Performance in the last:
Follow this Portfolio
1D 0.2 %
1W 1.1 %
2W 1.1 %
1M -1.4 %
3M 0.8 %
6M 2.7 %
9M -2.4 %
1Y 32.7 %
Alpha
18.3%
Beta
0.45
sharpe-R
1.24
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
2.64
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2024-12-03 08:16:55
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -9.45%
Max. DrawDown Benchmark -8.41%

This Long Only strategy aims to find promising assets to invest in for a maximum holding period of 1 Week in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 10.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
2

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 10.52% 8.55%
MGNX MacroGenics, Inc. Buy 10.52% 8.53%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 9.76% 0.73%
ESPR Esperion Therapeutics, Inc. Buy 9.6% 0%
The percentage of cash held in the portfolio is: 59.6%
** The description of each asset is available Here

The latest 5 Compositions change

2024-12-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 10.52% 8.55%
MGNX MacroGenics, Inc. Buy 10.52% 8.53%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 9.76% 0.73%
ESPR Esperion Therapeutics, Inc. Buy 9.6% 0%
The percentage of cash held in the portfolio is: 59.6%
New Assets Added
  • ESPR
Assets Removed
Asset Action Perf %
FATE Sell All -6.62%
Assets Rebalanced
None
2024-11-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 10.14% 4.63%
MGNX MacroGenics, Inc. Buy 10.37% 7.06%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 9.69% 0%
FATE Fate Therapeutics, Inc. Buy 9.69% 0%
The percentage of cash held in the portfolio is: 60.12%
New Assets Added
  • ARWR
  • FATE
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 9.8% 0%
MGNX MacroGenics, Inc. Buy 9.8% 0%
The percentage of cash held in the portfolio is: 80.4%
New Assets Added
  • APLS
  • MGNX
Assets Removed
None
Assets Rebalanced
None
2024-11-19 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
MDRX Sell All -4.98%
Assets Rebalanced
None
2024-11-18 00:00:00 : Portfolio change date
Asset Action Weight PnL
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.39% -5.24%
The percentage of cash held in the portfolio is: 89.61%
New Assets Added
None
Assets Removed
Asset Action Perf %
RGEN Sell All -17.11%
TGTX Sell All -3.9%
ITGR Sell All -2.62%
FGEN Sell All 3.72%
Assets Rebalanced
None
2024-11-15 00:00:00 : Portfolio change date
Asset Action Weight PnL
ITGR Integer Holdings Corporation Buy 9.46% -1.41%
FGEN FibroGen, Inc. Buy 10.99% 14.55%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.23% -3.91%
TGTX TG Therapeutics, Inc. Buy 10.69% 0.34%
RGEN Repligen Corporation Buy 9.17% -5.34%
The percentage of cash held in the portfolio is: 49.46%
New Assets Added
None
Assets Removed
Asset Action Perf %
SAGE Sell All -15.03%
CHRS Sell All -5.73%
Assets Rebalanced
None
2024-11-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
SAGE Sage Therapeutics, Inc. Buy 9.1% -9.34%
CHRS Coherus BioSciences, Inc. Buy 9.54% -5%
ITGR Integer Holdings Corporation Buy 9.46% 0.58%
FGEN FibroGen, Inc. Buy 9.67% 2.79%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.35% -0.89%
TGTX TG Therapeutics, Inc. Buy 11.86% 13.53%
RGEN Repligen Corporation Buy 9.5% 0%
The percentage of cash held in the portfolio is: 30.51%
New Assets Added
  • RGEN
Assets Removed
Asset Action Perf %
ARCT Sell All -2.29%
CARA Sell All -6.09%
HUM Sell All 0.32%
ESPR Sell All -11.51%
Assets Rebalanced
None
2024-11-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
HUM Humana Inc. Buy 9.68% -2.1%
CARA Cara Therapeutics, Inc. Buy 9.74% -1.16%
SAGE Sage Therapeutics, Inc. Buy 9.82% -0.32%
CHRS Coherus BioSciences, Inc. Buy 9.36% -5%
ITGR Integer Holdings Corporation Buy 9.41% 2%
ARCT Arcturus Therapeutics Holdings Inc. Buy 9.57% 3.77%
FGEN FibroGen, Inc. Buy 9.68% 4.95%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.25% 0%
ESPR Esperion Therapeutics, Inc. Buy 10.25% 0%
TGTX TG Therapeutics, Inc. Buy 10.25% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MDRX
  • ESPR
  • TGTX
Assets Removed
Asset Action Perf %
IRTC Sell All 9.2%
CORT Sell All 17.98%
Assets Rebalanced
None
2024-11-11 00:00:00 : Portfolio change date
Asset Action Weight PnL
IRTC iRhythm Technologies, Inc. Buy 10.12% 6.19%
CORT Corcept Therapeutics Incorporated Buy 11.34% 19.06%
HUM Humana Inc. Buy 9.93% -0.14%
CARA Cara Therapeutics, Inc. Buy 9.76% -1.45%
SAGE Sage Therapeutics, Inc. Buy 9.89% -0.16%
CHRS Coherus BioSciences, Inc. Buy 9.84% -0.61%
ITGR Integer Holdings Corporation Buy 9.28% 0%
ARCT Arcturus Therapeutics Holdings Inc. Buy 9.28% 0%
FGEN FibroGen, Inc. Buy 9.28% 0%
The percentage of cash held in the portfolio is: 11.28%
New Assets Added
  • ITGR
  • ARCT
  • FGEN
Assets Removed
Asset Action Perf %
AMN Sell All -29.49%
IART Sell All -0.52%
MGNX Sell All 12.4%
Assets Rebalanced
None
2024-11-08 00:00:00 : Portfolio change date
Asset Action Weight PnL
MGNX MacroGenics, Inc. Buy 10.47% 15.25%
IRTC iRhythm Technologies, Inc. Buy 10.09% 8.99%
CORT Corcept Therapeutics Incorporated Buy 10.04% 8.47%
IART Integra LifeSciences Holdings Corporation Buy 9.63% 2.41%
HUM Humana Inc. Buy 9.64% -0.26%
AMN AMN Healthcare Services, Inc. Buy 9.6% -0.68%
CARA Cara Therapeutics, Inc. Buy 9.63% 0%
SAGE Sage Therapeutics, Inc. Buy 9.63% 0%
CHRS Coherus BioSciences, Inc. Buy 9.63% 0%
The percentage of cash held in the portfolio is: 11.63%
New Assets Added
  • CARA
  • SAGE
  • CHRS
Assets Removed
Asset Action Perf %
ATEC Sell All 19.87%
AVXL Sell All 15.33%
MCRB Sell All -12.8%
ORMP Sell All 0%
Assets Rebalanced
None
2024-11-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
ATEC Alphatec Holdings, Inc. Buy 10.32% 12.99%
AVXL Anavex Life Sciences Corp. Buy 10.74% 17.67%
MCRB Seres Therapeutics, Inc. Buy 8.41% -7.93%
ORMP Oramed Pharmaceuticals Inc. Buy 8.98% -1.68%
MGNX MacroGenics, Inc. Buy 9.85% 8.27%
IRTC iRhythm Technologies, Inc. Buy 10.19% 9.9%
CORT Corcept Therapeutics Incorporated Buy 10.05% 8.33%
IART Integra LifeSciences Holdings Corporation Buy 10.1% 7.19%
HUM Humana Inc. Buy 9.68% 0%
AMN AMN Healthcare Services, Inc. Buy 9.68% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HUM
  • AMN
Assets Removed
Asset Action Perf %
NVRO Sell All 7.04%
INCY Sell All 9.5%
Assets Rebalanced
None
2024-11-06 00:00:00 : Portfolio change date
Asset Action Weight PnL
NVRO Nevro Corp. Buy 9.52% 2.96%
INCY Incyte Corporation Buy 9.67% 4.53%
ATEC Alphatec Holdings, Inc. Buy 10.29% 9.3%
AVXL Anavex Life Sciences Corp. Buy 10.95% 16.31%
MCRB Seres Therapeutics, Inc. Buy 9.32% -0.98%
ORMP Oramed Pharmaceuticals Inc. Buy 9.29% -1.26%
MGNX MacroGenics, Inc. Buy 9.14% -2.58%
IRTC iRhythm Technologies, Inc. Buy 10.17% 6.43%
CORT Corcept Therapeutics Incorporated Buy 9.95% 4.16%
IART Integra LifeSciences Holdings Corporation Buy 9.71% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • IART
Assets Removed
Asset Action Perf %
NEOG Sell All 4.74%
Assets Rebalanced
None
2024-11-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
NEOG Neogen Corporation Buy 9.66% 0.63%
NVRO Nevro Corp. Buy 9.43% -0.93%
INCY Incyte Corporation Buy 9.75% 2.46%
ATEC Alphatec Holdings, Inc. Buy 10.32% 6.5%
AVXL Anavex Life Sciences Corp. Buy 10.68% 10.27%
MCRB Seres Therapeutics, Inc. Buy 9.53% -1.59%
ORMP Oramed Pharmaceuticals Inc. Buy 9.73% 0.42%
MGNX MacroGenics, Inc. Buy 9.23% -4.39%
IRTC iRhythm Technologies, Inc. Buy 9.84% 0%
CORT Corcept Therapeutics Incorporated Buy 9.84% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • IRTC
  • CORT
Assets Removed
Asset Action Perf %
HCSG Sell All 2.01%
IOVA Sell All 3.72%
Assets Rebalanced
None
2024-11-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
HCSG Healthcare Services Group, Inc. Buy 9.8% 1.83%
IOVA Iovance Biotherapeutics, Inc. Buy 9.76% 1.45%
NEOG Neogen Corporation Buy 9.72% 0.7%
NVRO Nevro Corp. Buy 9.8% 2.41%
INCY Incyte Corporation Buy 9.85% 2.98%
ATEC Alphatec Holdings, Inc. Buy 10.06% 3.31%
AVXL Anavex Life Sciences Corp. Buy 10.05% 3.25%
MCRB Seres Therapeutics, Inc. Buy 9.76% 0.24%
ORMP Oramed Pharmaceuticals Inc. Buy 9.49% -2.52%
MGNX MacroGenics, Inc. Buy 9.71% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MGNX
Assets Removed
None
Assets Rebalanced
None
2024-11-01 00:00:00 : Portfolio change date
Asset Action Weight PnL
HCSG Healthcare Services Group, Inc. Buy 9.8% 0.18%
IOVA Iovance Biotherapeutics, Inc. Buy 9.26% -5.35%
NEOG Neogen Corporation Buy 9.77% -0.42%
NVRO Nevro Corp. Buy 9.93% 2.04%
INCY Incyte Corporation Buy 9.75% 0.26%
ATEC Alphatec Holdings, Inc. Buy 9.9% 0%
AVXL Anavex Life Sciences Corp. Buy 9.9% 0%
MCRB Seres Therapeutics, Inc. Buy 9.9% 0%
ORMP Oramed Pharmaceuticals Inc. Buy 9.9% 0%
The percentage of cash held in the portfolio is: 11.9%
New Assets Added
  • ATEC
  • AVXL
  • MCRB
  • ORMP
Assets Removed
Asset Action Perf %
VKTX Sell All -0.93%
IBRX Sell All 23.75%
SGMO Sell All -16.67%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings